 Loading
|
Take control of your epilepsy and seizures. Seizure management has never been easier.
TAKE CONTROL TODAYAs of May 15, 2007, rufinamide has not been approved for use in the United States. The U.S. Food and Drug Administration is currently determining whether to approve rufinamide as 1) add-on therapy for partial seizures with or without secondary generalization in adults and adolescents 12 years of age and older, and 2) add-on therapy for Lennox-Gastaut syndrome in children ages 4 and over.
In the European Union countries, Inovelon® was approved in January 2007 as add-on therapy for the treatment of Lennox-Gastaut syndrome.
Reviewed by Steven C. Schachter, MD
Submitted: 05/16/07
Welcome to the Wiki. This space is created for epilepsy.com members to share their own experiences and expertise to help refine and expand the discussion around important topics.
No members have yet contributed to this topic. If you are not yet an epilepsy.com member, register today to get started on this Wiki topic and the many other advantages of being a member. If you are a member and wish to be the first to edit this Wiki topic, please make sure to login, then click on the orange "Start Wiki" button at the top of this page. Or, learn more about Wikis.